Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

K. A. Jaeckle, A. Mittelman, F. H. Hill

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77+ weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58+, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129+ weeks, respectively. Overall, median time to progression and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

Original languageEnglish (US)
Pages (from-to)1408-1418
Number of pages11
JournalJournal of Clinical Oncology
Volume8
Issue number8
StatePublished - 1990
Externally publishedYes

Fingerprint

Serratia marcescens
Astrocytoma
Chills
Survival
Arthralgia
Erythema
Carbon Monoxide
Hypotension
Nausea
Vomiting
Headache
Fever
Radiotherapy
Observation
Technology
Drug Therapy
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jaeckle, K. A., Mittelman, A., & Hill, F. H. (1990). Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. Journal of Clinical Oncology, 8(8), 1408-1418.

Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. / Jaeckle, K. A.; Mittelman, A.; Hill, F. H.

In: Journal of Clinical Oncology, Vol. 8, No. 8, 1990, p. 1408-1418.

Research output: Contribution to journalArticle

Jaeckle, KA, Mittelman, A & Hill, FH 1990, 'Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma', Journal of Clinical Oncology, vol. 8, no. 8, pp. 1408-1418.
Jaeckle, K. A. ; Mittelman, A. ; Hill, F. H. / Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 8. pp. 1408-1418.
@article{e1f924fcbd434af3831e5dd8c5a2f7ff,
title = "Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma",
abstract = "Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77+ weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58+, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129+ weeks, respectively. Overall, median time to progression and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16{\%}). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.",
author = "Jaeckle, {K. A.} and A. Mittelman and Hill, {F. H.}",
year = "1990",
language = "English (US)",
volume = "8",
pages = "1408--1418",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

AU - Jaeckle, K. A.

AU - Mittelman, A.

AU - Hill, F. H.

PY - 1990

Y1 - 1990

N2 - Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77+ weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58+, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129+ weeks, respectively. Overall, median time to progression and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

AB - Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier (BRM). Two complete responses (CRs) were seen, of 63 and 77+ weeks duration. One minor response (MR) occurred, of 6 weeks duration. There were four additional stable (S) patients, with durations of 58+, 39, 12, and 7 weeks. Median time to progression and median survival in the CR plus MR patients were 63 and 129+ weeks, respectively. Overall, median time to progression and median survival were 12 and 19 weeks, respectively. Three patients are alive ≥ 2.5 years from study entry. Common toxicities included transient (< 72 hours) tenderness, induration, and erythema at the injection sites. Systemic toxicities were less frequent and included fever, chills, nausea/vomiting, headache, arthralgia, and hypotension. The response rate (CR plus MR) to this new BRM is modest (16%). However, the observation of CRs in patients with advanced recurrent malignant astrocytomas, with acceptable overall toxicity, warrants further study of this agent.

UR - http://www.scopus.com/inward/record.url?scp=0025076358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025076358&partnerID=8YFLogxK

M3 - Article

C2 - 2199624

AN - SCOPUS:0025076358

VL - 8

SP - 1408

EP - 1418

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -